Aviva PLC Has $748,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Aviva PLC reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 76.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,174 shares of the company’s stock after selling 200,187 shares during the period. Aviva PLC’s holdings in Elanco Animal Health were worth $748,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ELAN. Price T Rowe Associates Inc. MD increased its holdings in shares of Elanco Animal Health by 22.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 27,030,888 shares of the company’s stock valued at $335,454,000 after purchasing an additional 4,872,640 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new position in shares of Elanco Animal Health in the first quarter valued at $83,259,000. The Manufacturers Life Insurance Company increased its holdings in shares of Elanco Animal Health by 286.5% in the third quarter. The Manufacturers Life Insurance Company now owns 4,062,666 shares of the company’s stock valued at $50,430,000 after purchasing an additional 3,011,622 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Elanco Animal Health by 6.6% in the first quarter. BlackRock Inc. now owns 26,217,917 shares of the company’s stock valued at $684,027,000 after purchasing an additional 1,631,045 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Elanco Animal Health by 14.6% in the first quarter. Goldman Sachs Group Inc. now owns 12,105,226 shares of the company’s stock valued at $315,825,000 after purchasing an additional 1,541,163 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ELAN. Barclays upgraded shares of Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $14.00 price target on the stock in a research note on Thursday, April 20th. Morgan Stanley decreased their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Monday, January 30th. Finally, Piper Sandler decreased their price target on shares of Elanco Animal Health from $15.00 to $12.00 in a research note on Thursday, March 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $16.50.

Elanco Animal Health Trading Down 2.2 %

Shares of Elanco Animal Health stock opened at $8.51 on Monday. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -212.70, a PEG ratio of 6.14 and a beta of 0.92. The company has a quick ratio of 1.24, a current ratio of 2.25 and a debt-to-equity ratio of 0.75. Elanco Animal Health Incorporated has a 12-month low of $8.48 and a 12-month high of $24.93. The firm’s 50-day moving average price is $9.20 and its two-hundred day moving average price is $11.36.

Elanco Animal Health (NYSE:ELAN – Get Rating) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.16. The firm had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a negative net margin of 0.49% and a positive return on equity of 8.21%. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.36 earnings per share. On average, analysts forecast that Elanco Animal Health Incorporated will post 0.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director R David Hoover acquired 10,000 shares of Elanco Animal Health stock in a transaction on Friday, March 3rd. The shares were purchased at an average cost of $11.13 per share, for a total transaction of $111,300.00. Following the completion of the purchase, the director now directly owns 155,000 shares of the company’s stock, valued at approximately $1,725,150. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Jeffrey N. Simmons bought 15,000 shares of the company’s stock in a transaction dated Friday, March 10th. The stock was purchased at an average price of $9.60 per share, with a total value of $144,000.00. Following the completion of the acquisition, the chief executive officer now owns 45,000 shares of the company’s stock, valued at $432,000. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director R David Hoover bought 10,000 shares of the company’s stock in a transaction dated Friday, March 3rd. The stock was bought at an average cost of $11.13 per share, with a total value of $111,300.00. Following the acquisition, the director now directly owns 155,000 shares of the company’s stock, valued at approximately $1,725,150. The disclosure for this purchase can be found here. Corporate insiders own 6.40% of the company’s stock.

Elanco Animal Health Profile

(Get Rating)

Elanco Animal Health, Inc innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.